Carregant...
Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets
Today, monoclonal antibodies (mAbs) are a widespread and necessary tool for biomedical science. In the hematological cancer field, since rituximab became the first mAb approved by the Food and Drug Administration for the treatment of B-cell malignancies, a number of effective mAbs targeting lineage-...
Guardat en:
| Publicat a: | Front Immunol |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5776327/ https://ncbi.nlm.nih.gov/pubmed/29387053 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2017.01936 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|